Single and multiple dose pharmacokinetics of fleroxacin. 1988

E Weidekamm, and R Portmann, and C Partos, and D Dell
Department of Clinical Research, F. Hoffmann-La Roche, Basel, Switzerland.

Pharmacokinetics of fleroxacin following single and multiple dosing were studied in healthy male volunteers. The characteristics of this new trifluorinated quinolone are the long elimination half-life of approximately 10 h and the high plasma concentrations, which exceed 2 mg/l after an oral dose of 200 mg. These two parameters are a prerequisite for a once daily dosage regimen. A good linear relationship (r = 0.998) was found between administered doses (100-2500 mg) and resulting AUC values. The volume of distribution (Vss) exceeded 1 l/kg and reflects the good tissue penetration. Renal clearance of unbound drug was 104 ml/min and within three days 56% of the dose could be recovered from urine as unchanged drug. Multiple dosing of 800 or 1200 mg fleroxacin once daily over ten days resulted in an accumulation of the drug in the plasma by a factor of 1.4. This value is in agreement with the theoretically predicted accumulation and thus non-linear, time-dependent pharmacokinetics can be excluded. The administered tablets were completely bioavailable (F = 1.0) and a significant first pass metabolism can therefore be excluded.

UI MeSH Term Description Entries
D008297 Male Males
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D016576 Fleroxacin A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE. AM-833,Quinodis,Ro 23-6240,AM 833,AM833,Ro 23 6240,Ro 236240

Related Publications

E Weidekamm, and R Portmann, and C Partos, and D Dell
January 1995, Drugs,
E Weidekamm, and R Portmann, and C Partos, and D Dell
March 1978, European journal of clinical pharmacology,
E Weidekamm, and R Portmann, and C Partos, and D Dell
April 1986, European journal of clinical microbiology,
E Weidekamm, and R Portmann, and C Partos, and D Dell
October 1988, Antimicrobial agents and chemotherapy,
E Weidekamm, and R Portmann, and C Partos, and D Dell
January 2003, Journal of clinical pharmacology,
E Weidekamm, and R Portmann, and C Partos, and D Dell
February 1992, Clinical pharmacokinetics,
E Weidekamm, and R Portmann, and C Partos, and D Dell
April 2017, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,
E Weidekamm, and R Portmann, and C Partos, and D Dell
November 2017, Clinical and translational science,
E Weidekamm, and R Portmann, and C Partos, and D Dell
January 1988, European journal of clinical pharmacology,
E Weidekamm, and R Portmann, and C Partos, and D Dell
March 1994, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!